Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pipeline Analysis

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1752928

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1752928

Cutaneous and Systemic Leishmaniasis

PUBLISHED:
PAGES: 473 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Cutaneous and Systemic Leishmaniasis Market to Reach US$393.1 Million by 2030

The global market for Cutaneous and Systemic Leishmaniasis estimated at US$354.8 Million in the year 2024, is expected to reach US$393.1 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2024-2030. Pentavalent Antimonials Drug Class, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$220.5 Million by the end of the analysis period. Growth in the Antifungals Drug Class segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$96.7 Million While China is Forecast to Grow at 3.2% CAGR

The Cutaneous and Systemic Leishmaniasis market in the U.S. is estimated at US$96.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$72.1 Million by the year 2030 trailing a CAGR of 3.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Cutaneous and Systemic Leishmaniasis Market - Key Trends & Drivers Summarized

Why Is Leishmaniasis a Critical Focus Area in Global Infectious Disease Management?

Cutaneous and systemic leishmaniasis represent two of the most challenging neglected tropical diseases, caused by protozoan parasites of the Leishmania genus, transmitted through the bite of infected sandflies. Cutaneous leishmaniasis primarily affects the skin, causing ulcers and disfiguring lesions, while systemic or visceral leishmaniasis-also known as kala-azar-is far more severe, impacting internal organs such as the liver, spleen, and bone marrow and can be fatal if left untreated. Both forms of the disease disproportionately affect populations in low- and middle-income regions, particularly in parts of South Asia, Africa, Latin America, and the Middle East.

Despite being endemic to over 90 countries, leishmaniasis remains underdiagnosed and underfunded. Poor sanitation, climate change, human migration, and deforestation are accelerating its transmission. The increasing incidence of treatment-resistant strains, coinfections with HIV, and the limited availability of effective, safe, and affordable therapies underscore the urgency for improved diagnostic tools, novel therapeutics, and preventive strategies. As public health agencies and global organizations intensify focus on controlling neglected tropical diseases, the medical and pharmaceutical sectors are responding with renewed R&D into innovative leishmaniasis treatments.

What Therapeutic Approaches and Diagnostic Advancements Are Reshaping Disease Management?

Current treatment options for cutaneous and systemic leishmaniasis include antimonial compounds, amphotericin B, miltefosine, and paromomycin. However, many of these therapies have significant limitations, including toxicity, lengthy treatment durations, parenteral administration, and variable efficacy across parasite species. In systemic leishmaniasis, liposomal amphotericin B has become a preferred option in certain regions due to better safety profiles, though access remains limited by cost and logistical barriers. Combination therapies are being explored to enhance efficacy, reduce resistance, and shorten treatment regimens.

On the diagnostic front, traditional parasitological methods are being supplemented with molecular diagnostics (e.g., PCR-based assays) and rapid antigen detection tests, improving early-stage diagnosis and treatment monitoring. In cutaneous forms, dermal smear microscopy and histopathological examinations remain widely used, though newer point-of-care diagnostic kits are gaining ground in rural health systems. Research is also focused on identifying vaccine candidates and developing novel drug delivery systems such as liposomal formulations and transdermal patches that offer improved targeting and reduced side effects.

Which Regions and Patient Segments Are Most Affected by the Disease Burden?

The highest prevalence of cutaneous leishmaniasis is found in Afghanistan, Syria, Brazil, Iran, and Pakistan, where social instability, vector proliferation, and limited healthcare infrastructure exacerbate disease spread. Visceral leishmaniasis remains endemic in India, Sudan, Ethiopia, and Bangladesh, particularly affecting impoverished rural populations with low access to healthcare. Children, immunocompromised individuals, and those co-infected with HIV are particularly vulnerable to visceral forms of the disease, with higher fatality rates and poorer treatment outcomes.

Refugee populations, labor migrants, and residents of conflict zones are increasingly affected due to the collapse of disease control programs and rising exposure to sandfly habitats. Urban expansion into forested or agricultural areas is also increasing the human-vector interface, further driving transmission. Mass drug administration programs, community awareness campaigns, and vector control initiatives remain critical in these high-burden areas, although challenges in funding, diagnostics, and logistics continue to limit impact.

What Factors Are Driving Growth in the Cutaneous and Systemic Leishmaniasis Treatment Market?

The growth in the cutaneous and systemic leishmaniasis market is driven by several interrelated public health, pharmaceutical, and environmental factors. Rising global attention to neglected tropical diseases and increasing funding from non-governmental organizations and public health agencies are fueling research into more effective and accessible treatment options. The expanding pipeline of drug candidates-including oral therapies, nano-formulations, and immunomodulators-is introducing new avenues for safer, shorter, and more scalable treatment regimens.

Growing support for public-private partnerships is enabling collaborative drug development, distribution, and data-sharing initiatives to address endemic needs. The intensifying intersection of leishmaniasis with other public health issues, such as HIV and malnutrition, is driving integrated healthcare responses and broader screening initiatives. Lastly, innovations in vector surveillance, climate-based risk mapping, and mobile diagnostics are improving early detection and intervention capabilities. These dynamics collectively underscore a growing commitment to eliminating leishmaniasis as a public health threat and expanding market opportunities for therapeutic and diagnostic innovation.

SCOPE OF STUDY:

The report analyzes the Cutaneous and Systemic Leishmaniasis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Pentavalent Antimonials Drug Class, Antifungals Drug Class, Anti-Lesihmanial / Antimicrobials Drug Class); Administration Route (Oral Route, Injectable Route, Topical Route); Indication (Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication, Visceral Leishmaniasis Indication); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Albert David Ltd.
  • Bayer AG
  • Biocon Limited
  • BioLineRx Ltd.
  • Bristol-Myers Squibb
  • Camurus AB
  • DNDi
  • Eisai Co., Ltd.
  • Endo Pharmaceuticals
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Global Services
  • Jubilant Life Sciences
  • Knight Therapeutics Inc.
  • Novartis AG
  • Pfizer Inc.
  • Protalix BioTherapeutics
  • Sanofi
  • Takeda Pharmaceutical
  • United Biotech Pvt. Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36650

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Cutaneous and Systemic Leishmaniasis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence in Endemic Regions Propels Global Demand for Leishmaniasis Diagnostics and Therapeutics
    • Expansion of Public Health Surveillance Initiatives Strengthens Case for Early Detection Solutions
    • Growing Investments in Tropical Disease Research Throws the Spotlight on Leishmaniasis Drug Development
    • Limited Treatment Access in Developing Regions Spurs Need for Affordable Therapeutic Options
    • Global Health NGO and Government Partnerships Accelerate Mass Screening and Awareness Campaigns
    • Emerging Drug Resistance Patterns in Leishmania Parasites Drive Innovation in Antileishmanial Compounds
    • Increased Adoption of Liposomal Amphotericin B Sustains Market for Targeted Systemic Therapies
    • Climate Change and Human Migration Expand Leishmaniasis Transmission Zones Globally
    • Demand for Point-of-Care Diagnostics Strengthens Market for Field-Deployable Detection Kits
    • Focus on Animal Reservoir Control Boosts Demand for Vector Control and Zoonotic Prevention Tools
    • R&D Advances in Vaccine Development Create Long-Term Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cutaneous and Systemic Leishmaniasis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pentavalent Antimonials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antifungals Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Topical Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Cutaneous Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Mucosal Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Visceral Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • JAPAN
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • CHINA
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • EUROPE
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • FRANCE
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • GERMANY
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • INDIA
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 319: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 331: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 334: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 343: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 346: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 355: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 370: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 379: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
  • AFRICA
    • Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 394: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 403: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!